[zn2(μ-cl)2(hpclnol)2](clo4)2

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Conselho Nacional de Desenvolvimento Científico e Tecnológico and 2 more

Cells1

Outcomes

Protein carbonylation

downin yeast cells1

1 study

[zn2(μ-cl)2(hpclnol)2](clo4)2 decreases protein carbonylation in yeast cells.
“aged cells showing reduced lipid peroxidation and protein carbonylation.”
Cellsin aged cells
Antioxidant and anti-aging properties of a Zn-complex in Saccharomyces cerevisiae: A non-canonical protective mechanism
Journal of inorganic biochemistry18 Mar 2026

Latest

1 in 12 months

Journal of Inorganic Biochemistry26 Mar

Antioxidant and anti-aging properties of a Zn-complex in Saccharomyces cerevisiae: A non-canonical protective mechanism

Experiments in yeastInterventions

Paper

[zn2(μ-cl)2(hpclnol)2](clo4)2

Outcomes

Latest

Antioxidant and anti-aging properties of a Zn-complex in Saccharomyces cerevisiae: A non-canonical protective mechanism

Related